Login
Existing Account

Please login first to complete purchase/ quotation request, view custom order reports, or create favorites list.

Customer ID:
Password:
Stay Logged In


Forgot your Customer ID or Password?
New Account

Don't have an account with us yet? Please set up an account to place order or obtain customer services.

Assay Kits  >  MMP Assay Kits  >>  SensoLyte® 520 MMP-13 Assay Kit *Fluorimetric*

Product Name SensoLyte® 520 MMP - 13 Assay Kit *Fluorimetric*
Size 1 kit
Catalog # 71156
US$ $435
Description

Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated proteins capable of digesting extracellular matrix components. MMP-13 (collagenase-3, rat collagenase) is involved in quite a few diseases such as arthritis and asthma. The SensoLyte® 520 MMP-13 Assay Kit uses a 5-FAM (fluorophore) and QXL® 520 (quencher) labeled FRET peptide substrates for continuous measurement of the enzyme activities. In an intact FRET peptide, the fluorescence of 5-FAM is quenched by QXL® 520. Upon the cleavage of the FRET peptide by MMP-13, the fluorescence of 5-FAM is recovered, and can be continuously monitored at excitation/emission = 490 nm/520 nm. With superior fluorescence quantum yield and longer emission wavelength, 5-FAM/QXL® 520 based FRET peptide is less interfered by the autofluorescence of test compounds and cellular components and provides better assay sensitivity. The assays are performed in a convenient 96-well or 384-well microplate format. Members of the MMP family have poor substrate sequence specificity, making it difficult to use a peptide substrate alone to differentiate the activity of a particular MMP from other MMPs. If several MMPs are coexisting in your samples and you would like to specifically measure MMP-13 activity, please choose the SensoLyte® Plus MMP-13 Assay Kit, Cat# 72019.

Kit size:100 assays

Detailed Information Datasheet
Material Safety Data Sheets (MSDS)
Brochure
Storage -20°C
Product Citations Wang, M. et al. (2013). MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res Therapy 15, R5.
Jaffré, F. et al. (2012). β-Adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation 125, 2993. doi:10.1161/​CIRCULATIONAHA.111.066787
Wigner, NA. et al. (2011). Urine matrix metalloproteinases (MMPSs) as biomarkers for the progression of fracture healing. Injury 10.1016/j.injury.2011.05.038.
Madala, SK. et al. (2010). Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis. J Immunol 184, 3955.
Bedi, A. et al. (2009). Doxycycline-mediated inhibition of matrix metalloproteinases improves healing after rotator cuff repair. Am J Sports Med 38, 308.
Arnoczky, SP. et al. (2007). Matrix metalloproteinase inhibitors prevent a decrease in the mechanical properties of stress-deprived tendons: an in vitro experimental study. Am J Sports Med 35, 763.
     
  < Back